We are live on ! Find out more
GC

Guggenheim Capital Portfolio holdings

AUM $12.9B
1-Year Est. Return 27.3%
This Fund
S&P 500
This Quarter Est. Return
+4.88%
1 Year Est. Return
+27.3%
3 Year Est. Return
+83.37%
5 Year Est. Return
+104.66%
10 Year Est. Return
+359.15%
AUM
$39.9B
AUM Growth
-$1.85B
Cap. Flow
-$120M
Cap. Flow %
-0.3%
Top 10 Hldgs %
5.46%
Holding
3,261
New
279
Increased
1,342
Reduced
1,357
Closed
256

Top Sells

Rank Stock Value
1
BG icon
Bunge Global
BG
+$67.6M
2
THG icon
Hanover Insurance
THG
+$63.6M
3
URS
URS CORP
URS
+$58.3M
4
GDX icon
VanEck Gold Miners ETF
GDX
+$58.3M
5
NTRS icon
Northern Trust
NTRS
+$49.8M

Sector Composition

Rank Sector Weight
1 Technology 11.6%
2 Healthcare 11.32%
3 Consumer Discretionary 10.79%
4 Financials 10.35%
5 Industrials 9.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
WYY icon
2976
WidePoint Corp
WYY
$106M
$16K ﹤0.01%
+1,141
New +$17K
VRNG
2977
DELISTED
VRINGO, INC COM STK NEW (DE)
VRNG
$16K ﹤0.01%
+2,897
New +$24.5K
URZ
2978
DELISTED
URANERZ ENERGY CORP
URZ
$15K ﹤0.01%
13,675
+3,574
+35% +$4K
IPAS
2979
DELISTED
Ipass Inc Common Stock
IPAS
$15K ﹤0.01%
+1,084
New +$15.8K
ETRM
2980
DELISTED
EnteroMedics Inc.
ETRM
$15K ﹤0.01%
+10
New +$13.5K
OMEX icon
2981
Odyssey Marine Exploration
OMEX
$43.2M
$14K ﹤0.01%
1,293
+420
+48% +$5.34K
ANAD
2982
DELISTED
ANADIGICS INC
ANAD
$14K ﹤0.01%
+18,183
New +$13K
EOX
2983
DELISTED
EMERALD OIL INC (MT)
EOX
$14K ﹤0.01%
572
-191
-25% -$10.4K
DRRX
2984
DELISTED
DURECT Corp
DRRX
$13K ﹤0.01%
1,623
+298
+22% +$2.91K
WINT
2985
DELISTED
Windtree Therapeutics Inc
WINT
$13K ﹤0.01%
+820
New +$18K
SVRA icon
2986
Savara
SVRA
$1.11B
$12K ﹤0.01%
301
+110
+58% +$3.84K
FRTX
2987
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
$12K ﹤0.01%
+4
New +$14.2K
ARQL
2988
DELISTED
Arqule Inc
ARQL
$12K ﹤0.01%
+10,145
New +$12K
SES
2989
DELISTED
Synthesis Energy Systems Inc.
SES
$11K ﹤0.01%
+179
New +$11.3K
MDW
2990
DELISTED
MIDWAY GOLD CORP (CANADA)
MDW
$11K ﹤0.01%
15,254
+2,867
+23% +$2.33K
MBOT icon
2991
Microbot Medical
MBOT
$122M
$10K ﹤0.01%
+7
New +$12.7K
AVEO
2992
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$9K ﹤0.01%
+1,014
New +$9.27K
HTM
2993
DELISTED
U.S. Geothermal Inc.
HTM
$9K ﹤0.01%
3,337
+797
+31% +$2.42K
CRDC
2994
DELISTED
CARDICA INC COM NEW (DE)
CRDC
$9K ﹤0.01%
+1,353
New +$11.1K
IMUC
2995
DELISTED
ImmunoCellular Therapeutics, Ltd.
IMUC
$9K ﹤0.01%
+311
New +$8.95K
CVM icon
2996
CEL-SCI Corp
CVM
$23.8M
$8K ﹤0.01%
+17
New +$8.38K
GMO
2997
DELISTED
General Moly, Inc.
GMO
$8K ﹤0.01%
+14,555
New +$8.2K
AIM
2998
AIM ImmunoTech
AIM
$7.29M
$8K ﹤0.01%
+1
New +$14.9K
TMQ
2999
Trilogy Metals
TMQ
$594M
$7K ﹤0.01%
14,796
-549,720
-97% -$376K
RCPI
3000
DELISTED
ROCK CREEK PHARMACEUTICALS INC COM STK (DE)
RCPI
$6K ﹤0.01%
1,278
+445
+53% +$2.34K

Similar funds

Guggenheim Capital's Q4 2014 Portfolio in Review

As of Q4 2014, Guggenheim Capital held 3,261 positions worth $39.9B, down 4.4% from $41.7B the previous quarter. Its ten largest holdings account for 5.5% of the portfolio.

Guggenheim Capital's Q4 2014 filing shows 279 new, 1,342 increased, 1,357 reduced and 256 closed positions. Its largest new stake was Direxion Daily Gold Miners Index Bull 2X ETF: 71,350 shares worth $31.9M. The largest sale was Bunge Global, an estimated $67.6M.

By sector, the portfolio is most concentrated in Technology at 12% of assets, up from 9.9% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • Guggenheim Capital's largest Q4 2014 buy was Direxion Daily Gold Miners Index Bull 2X ETF: 71,350 shares worth $31.9M.
  • Guggenheim Capital added most to Invesco QQQ Trust in Q4 2014, an estimated $107M increase.
  • Guggenheim Capital's biggest Q4 2014 reduction was Bunge Global, cutting an estimated $67.6M.
  • Guggenheim Capital fully exited URS CORP in Q4 2014, selling an estimated $58.3M.
  • Guggenheim Capital's ten largest holdings make up 5.5% of its $39.9B portfolio in Q4 2014.
  • Guggenheim Capital opened 279 new positions and closed 256 in Q4 2014.
  • Guggenheim Capital's portfolio value fell 4.4% quarter-over-quarter to $39.9B.

Based on Guggenheim Capital's 13F filing for Q4 2014, filed 17 Feb 2015.